Totals
- Total revenue
- $423,518
- Total expenses
- $660,937
- Contributions and grants received
- $260,960
- Grants paid
- $100
- Program service revenue
- $157,697
- Investment income
- $4,861
- Other revenue
- $0
- Total assets, end of year
- $554,990
- Total liabilities, end of year
- $21,305
- Net assets or fund balances, end of year
- $533,685
- Program services expenses (Part IX)
- $551,518
- Management and general expenses
- $77,332
- Fundraising expenses
- $32,087
- Program service expenses (Part III)
- $551,518
Program services were 83.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1a · Federated campaigns
$0
-
1b · Membership dues
$161,801
-
1c · Fundraising events
$0
-
1d · Related organizations
$0
-
1e · Government grants (contributions)
$0
-
1f · All other contributions, gifts and grants
$99,159
-
1g · Noncash contributions included above
$0
-
2a · Program service revenue: DrugsData Lab Drug Checking Fees
total $136,494 · related or exempt $136,494 · unrelated business $0 · excluded $0
-
2b · Program service revenue: Research Improvement
total $15,881 · related or exempt $15,881 · unrelated business $0 · excluded $0
-
2c · Program service revenue: Educational Materials/Books
total $5,322 · related or exempt $5,322 · unrelated business $0 · excluded $0
-
2f · All other program service revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
3 · Investment income
total $4,861 · related or exempt $0 · unrelated business $0 · excluded $4,861
-
4 · Income from investment of tax-exempt bond proceeds
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
5 · Royalties
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
6a · Gross rents
real property $0 · personal property $0
-
6b · Less rental expenses
real property $0 · personal property $0
-
6c · Rental income or loss
real property $0 · personal property $0
-
6d · Net rental income or loss
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
7a · Gross sales of assets other than inventory
securities $0 · other assets $0
-
7b · Less cost or other basis and sales expenses
securities $0 · other assets $0
-
7c · Gain or loss
securities $0 · other assets $0
-
7d · Net gain or loss
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
8a · Fundraising events: gross income
$0
-
8a · Fundraising events: contributions included on line 1c
$0
-
8b · Fundraising events: direct expenses
$0
-
8c · Net income from fundraising events
total $0 · unrelated business $0 · excluded $0
-
9a · Gaming: gross income
$0
-
9b · Gaming: direct expenses
$0
-
9c · Net income from gaming
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
10a · Gross sales of inventory
$0
-
10b · Cost of goods sold
$0
-
10c · Net income from sales of inventory
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
11e · Other revenue, total
$0
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $100 · program services $100
-
2 · Grants to domestic individuals
total $0 · program services $0
-
3 · Grants to foreign organizations and individuals
total $0 · program services $0
-
4 · Benefits paid to or for members
total $0 · program services $0
-
5 · Compensation of officers, directors and key employees
total $200,620 · program services $142,440 · management and general $38,118 · fundraising $20,062
-
6 · Compensation of disqualified persons
total $0 · program services $0 · management and general $0 · fundraising $0
-
7 · Other salaries and wages
total $20,800 · program services $20,176 · management and general $624 · fundraising $0
-
8 · Pension plan contributions
total $16,200 · program services $15,714 · management and general $486 · fundraising $0
-
9 · Other employee benefits
total $0 · program services $0 · management and general $0 · fundraising $0
-
10 · Payroll taxes
total $14,904 · program services $11,185 · management and general $2,461 · fundraising $1,258
-
11a · Fees: management
total $0 · program services $0 · management and general $0 · fundraising $0
-
11b · Fees: legal
total $500 · program services $0 · management and general $500 · fundraising $0
-
11c · Fees: accounting
total $0 · program services $0 · management and general $0 · fundraising $0
-
11d · Fees: lobbying
total $0 · program services $0 · management and general $0 · fundraising $0
-
11e · Fees: professional fundraising services
total $0 · fundraising $0
-
11f · Fees: investment management
total $945 · program services $0 · management and general $945 · fundraising $0
-
11g · Fees: other
total $63,875 · program services $58,937 · management and general $4,704 · fundraising $234
-
12 · Advertising and promotion
total $3,826 · program services $1,148 · management and general $0 · fundraising $2,678
-
13 · Office expenses
total $22,082 · program services $7,707 · management and general $13,981 · fundraising $394
-
14 · Information technology
total $107,944 · program services $97,270 · management and general $8,693 · fundraising $1,981
-
15 · Royalties
total $0 · program services $0 · management and general $0 · fundraising $0
-
16 · Occupancy
total $24,082 · program services $17,919 · management and general $1,839 · fundraising $4,324
-
17 · Travel
total $2,977 · program services $2,257 · management and general $497 · fundraising $223
-
18 · Travel or entertainment for public officials
total $0 · program services $0 · management and general $0 · fundraising $0
-
19 · Conferences, conventions and meetings
total $0 · program services $0 · management and general $0 · fundraising $0
-
20 · Interest
total $4,021 · program services $0 · management and general $4,021 · fundraising $0
-
21 · Payments to affiliates
total $0 · program services $0 · management and general $0 · fundraising $0
-
22 · Depreciation, depletion and amortization
total $0 · program services $0 · management and general $0 · fundraising $0
-
23 · Insurance
total $819 · program services $410 · management and general $409 · fundraising $0
-
24a · Other expenses: DrugsData Lab Testing
total $175,775 · program services $175,775 · management and general $0 · fundraising $0
-
24b · Other expenses: Educational Materials
total $978 · program services $480 · management and general $54 · fundraising $444
-
24c · Other expenses: Postage
total $489 · program services $0 · management and general $0 · fundraising $489
-
24e · All other expenses
total $0 · program services $0 · management and general $0 · fundraising $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $55,127 · end of year $51,535
-
2 · Savings and temporary cash investments
beginning of year $64,299 · end of year $47,382
-
3 · Pledges and grants receivable
beginning of year $0 · end of year $0
-
4 · Accounts receivable
beginning of year $4,040 · end of year $2,004
-
5 · Loans and receivables from officers and key people
beginning of year $0 · end of year $0
-
6 · Loans and receivables from disqualified persons
beginning of year $0 · end of year $0
-
7 · Other notes and loans receivable
beginning of year $0 · end of year $0
-
8 · Inventories for sale or use
beginning of year $0 · end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $0 · end of year $0
-
11 · Investments: publicly traded securities
beginning of year $197,081 · end of year $80,050
-
12 · Investments: other securities
beginning of year $218,460 · end of year $374,019
-
13 · Investments: program-related
beginning of year $0 · end of year $0
-
14 · Intangible assets
beginning of year $0 · end of year $0
-
15 · Other assets
beginning of year $0 · end of year $0
-
17 · Accounts payable and accrued expenses
beginning of year $25,420 · end of year $21,305
-
18 · Grants payable
beginning of year $0 · end of year $0
-
19 · Deferred revenue
beginning of year $0 · end of year $0
-
20 · Tax-exempt bond liabilities
beginning of year $0 · end of year $0
-
21 · Escrow or custodial account liability
beginning of year $0 · end of year $0
-
22 · Loans and payables to officers and key people
beginning of year $0 · end of year $0
-
23 · Secured mortgages and notes payable
beginning of year $0 · end of year $0
-
24 · Unsecured notes and loans payable
beginning of year $0 · end of year $0
-
29 · Capital stock, trust principal or current funds
beginning of year $513,587 · end of year $533,685
-
30 · Paid-in or capital surplus, or land, building or equipment fund
beginning of year $0 · end of year $0
-
31 · Retained earnings, endowment or other funds
beginning of year $0 · end of year $0
Mission and programs · 2024
Mission
To provide & facilitate access to objective, accurate, and non-judgmental information about psychoactive plants chemicals, drugs, technologies, and related issues. Erowid also supports and trains information providers and assists medical, legal, and scientific experts in developing resources.
Activities or mission (Part I)
To provide & facilitate access to objective, accurate, and non-judgmental information about psychoactive plants, chemicals, drugs, technologies, and related issues. Erowid also supports and trains information providers and assists medical, legal, and scientific experts in developing resources.
-
Erowid Center runs a laboratory drug checking program that analyzes the contents of street samples of psychoactive drugs, including: novel psychoactive substances (NPS); stimulants and euphoric stimulants; psychedelics; research chemicals; street heroin; fentanyl; and other opioids; as well as commercial and counterfeit pharmaceuticals. Samples are tested at a licensed laboratory and the results are published online at DrugsData.org. Erowid's DrugsData project also collects, manages, reviews, and presents laboratory-testing results from other US and international organizations. This information is made publicly available to help harm-reduction efforts, medical personnel, researchers, and the public. In 2024, 1,001 samples were tested through this project and 199 unique substances were detected. These results were published alongside results for 799 samples tested by other organizations. An average of 30,000 result pages were viewed per day, with an average 15,000 unique visitors per day. Results were regularly published on social media to Erowid's more than 180,000 followers. Erowid continued its partnerships with research groups doing lab validation of on-site analytical tools such as compact FTIR and fentanyl and xylazine test strips. A portion of the expenses and revenue associated with DrugsData research are included in the Drug Trend & Novel Psychoactive Substance and Research program services described below. This service was interrupted on April 10, 2024, due to an unexpected regulatory change and was unable to conduct operations through the end of 2024.
Expenses $191,552 · Revenue $136,494
-
Erowid Center develops, maintains, and provides free access to an online collection of more than 96,700 documents, images, and other media files related to psychoactive plants and drugs. The collection contains information, essays and articles authored by a broad spectrum of contributors including health care professionals, substance abuse counselors, toxicologists, chemists, therapists, law enforcement agents, lawyers, anthropologists, experiential experts, writers, media, educators, and the general public. Note that Erowid's Experience Reports project is tracked as a separate program service. Erowid also shared information via social media accounts on Twitter, Instagram, and Facebook.
Expenses $119,090
-
Erowid Center's mission includes collecting, organizing, and preserving resources about psychoactives for the historical record. In 2024, Erowid's primary archiving project was the Shulgin Collection. Erowid nearly completed digitizing Alexander and Ann Shulgin's personal papers, audio recordings, and documents. Erowid also organized, identified, and created metadata for digitized files. By the end of the year, Erowid had created index entries for 55,000 scanned documents in the collection of around 230,000 total scanned items. Erowid Center maintains a physical space designed to allow processing of historical archive collections (organizing, scanning, photographing, and digitizing) as well as permanent storage of some library archives/collections.
Expenses $110,825
-
4. Research, Surveys, & Research Improvement - Research, Surveys, & Research Improvement - In 2024, Erowid co-authored 4 published peer-reviewed journal articles. We participated in writing and submitting two additional papers, not published in 2024. We worked on multiple scientific/medical research projects as part of the Lab Validation subproject of our DrugsData program. Erowid improves scientific, medical, and sociological information about psychoactive substances and those who use them by promoting participation in studies and surveys produced by academics, educational institutions, and related organizations. Erowid works directly with scientists-in areas where we have specialized knowledge-to help design credible studies and provide editing, reviewing, and fact-checking for resulting academic publications. Several additional papers were published in academic journals using Erowid's Experience Vault data as a major part of their primary dataset. Erowid Center's resources are referenced in hundreds of journal articles, books, and media articles each year.
Expenses $44,319 · Revenue $15,881
-
5. Drug Trend & Novel Psychoactive Substance Tracking - Tracking new psychoactive medicines, technologies, research chemicals, psychedelics, and novel psychoactive substances (NPS) is one of Erowid Center's areas of expertise. With the objective of educating the public on the risks and benefits associated with emerging drugs, we 1) monitor the availability, use patterns, and effects of these substances through consultation with volunteers, allied organizations, medical professionals, submissions, and online forums; 2) analyze psychoactive chemicals through our DrugsData program (tracked as a separate project); 3) coordinate between experts and researchers in the field; 4) educate writers and authors for media, news, and books; and 5) publish information about these substances, online and in print. In 2024, Erowid's DrugsData encountered 35 unidentifiable novel substances in submitted samples. With the help of a network of international experts, we were able to identify 14 of these. Erowid worked with multiple groups to monitor the contents of street 'heroin'/down/dope/fentanyl as well as cocaine and methamphetamine. Erowid helped identify and characterize contaminants, synthesis byproducts, and novel substances. We leveraged our expertise to help develop systems to mitigate the societal damage of the "opioid epidemic", improve state- and city-level drug supply monitoring, and provide facts to help public health messaging around misrepresented and contaminated street drugs.
Expenses $40,041
-
6. Education and Educational Materials, Books, and Gifts - Erowid provided direct education services by answering online questions from the public via email, social media, and other communication systems. Erowid maintains a social media presence via Instagram, Twitter, Facebook, and LinkedIn through which we publish new information, drug checking results, news and research updates, and answer questions related to psychoactives. We distribute books, handouts, and teaching materials about psychoactive drugs, plants, practices, and technologies to members and the general public, furthering our educational mission.
Expenses $18,015 · Revenue $4,951
-
7. Experience Reports Collection - Erowid Center solicited, reviewed, and published first-hand reports of people's experiences with psychoactive plants, drugs, and technologies. Erowid's Experience Reports generated information about novel and classic psychoactive materials as well as aggregate data about why and how people use psychoactives, both for current factual documentation and for the historical record. Researchers, academics, medical professionals, and the public use the results for educational purposes and as data for peer-reviewed articles and publications. Reports are reviewed and edited before being published. Trained volunteers perform a portion of the work under the supervision of Erowid staff. In 2024, Erowid crew completed 5,112 "triages" (reading and rating an experience report), review-edited for publication 285, and published 238, ending the year with 42,926 published reports in the collection covering 890 substances. Approximately 21 million experience reports were viewed during the year.
Expenses $15,306
-
8. Events & Conferences - Erowid conducts educational outreach in person and online at conferences, seminars, festivals, and meetings. In 2024, we had monthly technical meetings with research partners monitoring street drug contents and contaminants as part of our DrugsData project until August 2024. Erowid Center spoke and participated in a four-day online conference about drug checking, lab analysis, and in-person street drug user direct care.
Expenses $5,220
-
9. Information Network - EEN - Erowid Center works with a network of both professionally trained and self-taught experts with knowledge about psychoactive plants, chemicals, and technologies. Erowid Expert Network (EEN) members volunteer to share their expertise for the purpose of educating the public and improving the quality of information about this topic. The EEN facilitates making connections between those who are seeking information and experts who can help them. This furthers Erowid Center's mission by helping to improve both internal and external educational resources through increased fact checking and review.
Expenses $5,026
-
10. Erowid Extracts Educational Newsletter - Erowid Center continued to collect information for a future newsletter issue centered on public drug checking and our DrugsData laboratory drug checking program (program expenses tracked separately). This advertisement-free print publication is distributed to members when published and past issues are distributed for free at conferences we attend. A complete digital version and constituent articles are later published online for free access by the general public. More than 17,000 copies of previous issues of Erowid Extracts were viewed/downloaded in 2024, and thousands of people read individual articles from previous issues online. Back issues were also distributed worldwide for free to related organizations, members, and events.
Expenses $2,124
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
C Blomquist
Treasurer
- Total calculated
- $100,386
- From this org
- $81,000
- From related orgs
- $0
- Other
- $19,386
- Hours/week
- 50
-
B Lincoln
President
- Total calculated
- $100,386
- From this org
- $81,000
- From related orgs
- $0
- Other
- $19,386
- Hours/week
- 60
-
J Dumpert
Secretary
- Total calculated
- $0
- Hours/week
- 1
-
E Fenster
Director
- Total calculated
- $0
- Hours/week
- 0.7
-
S Moore
Director
- Total calculated
- $0
- Hours/week
- 0.5
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 28 October 2025
- IRS schema version
- 2024v5.0
- Source object
- 202523029349300802
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.